Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Proteostasis Therapeutics (PTI) Surges 50% on FDA Breakthrough Therapy Designation for PTI-428March 13, 2018 9:05 AM Proteostasis Therapeutics (PTI): Incrementally Positive on FDA Breakthrough Designation - BairdMarch 13, 2018 6:44 AM Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic FibrosisMarch 12, 2018 4:05 PM